Dutch cardio-oncology cohort: Incident cardiovascular disease predisposes to a higher cancer mortality rate

IF 4.4 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Yvonne Koop, Laura Yousif, Rudolf A. de Boer, Michiel L. Bots, Wouter C. Meijers, Ilonca Vaartjes
{"title":"Dutch cardio-oncology cohort: Incident cardiovascular disease predisposes to a higher cancer mortality rate","authors":"Yvonne Koop,&nbsp;Laura Yousif,&nbsp;Rudolf A. de Boer,&nbsp;Michiel L. Bots,&nbsp;Wouter C. Meijers,&nbsp;Ilonca Vaartjes","doi":"10.1111/eci.14255","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Cardiovascular disease (CVD) and cancer are the two leading causes of death worldwide. Given their high prevalence, it is important to understand the disease burden of cancer mortality in CVD patients.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>We aimed to evaluate whether patients with incident CVD have a higher risk of malignancy-related mortality, compared to the general population without CVD.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We performed a national population-based cohort study selecting patients with incident CVD in the Netherlands between 01 April 2000 and 31 December 2005. A reference cohort was selected from the Dutch population using age, sex and ethnicity. Mortality follow-up data were evaluated after data linkage of national registries from Statistics Netherlands until 31 December 2020.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 2,240,879 individuals were selected with a mean follow-up of 12 years (range 0.4–21.0), of which 738,666 patients with incident CVD with a mean age of 71 ± 15 years. Malignancy mortality per 1000 person years was 84 for the reference group and 118 for patients with CVD, with the highest rate of 258 in patients with heart failure. Patients with CVD had a higher malignancy mortality risk, compared to the reference group: HR 1.35 (95%CI 1.33–1.36). Highest risks were observed in patients with venous diseases (HR 2.27, 95%CI 2.17–2.36) and peripheral artery disease (HR 1.87, 95%CI 1.84–2.01).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Results show that CVD predisposes to a higher cancer mortality rate. Of all CVD subtypes, HF patients have the highest cancer mortality rate and the hazards were highest in patients with venous diseases and peripheral artery disease.</p>\n </section>\n </div>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":"54 9","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2024-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/eci.14255","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/eci.14255","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Cardiovascular disease (CVD) and cancer are the two leading causes of death worldwide. Given their high prevalence, it is important to understand the disease burden of cancer mortality in CVD patients.

Objective

We aimed to evaluate whether patients with incident CVD have a higher risk of malignancy-related mortality, compared to the general population without CVD.

Methods

We performed a national population-based cohort study selecting patients with incident CVD in the Netherlands between 01 April 2000 and 31 December 2005. A reference cohort was selected from the Dutch population using age, sex and ethnicity. Mortality follow-up data were evaluated after data linkage of national registries from Statistics Netherlands until 31 December 2020.

Results

A total of 2,240,879 individuals were selected with a mean follow-up of 12 years (range 0.4–21.0), of which 738,666 patients with incident CVD with a mean age of 71 ± 15 years. Malignancy mortality per 1000 person years was 84 for the reference group and 118 for patients with CVD, with the highest rate of 258 in patients with heart failure. Patients with CVD had a higher malignancy mortality risk, compared to the reference group: HR 1.35 (95%CI 1.33–1.36). Highest risks were observed in patients with venous diseases (HR 2.27, 95%CI 2.17–2.36) and peripheral artery disease (HR 1.87, 95%CI 1.84–2.01).

Conclusion

Results show that CVD predisposes to a higher cancer mortality rate. Of all CVD subtypes, HF patients have the highest cancer mortality rate and the hazards were highest in patients with venous diseases and peripheral artery disease.

Abstract Image

荷兰心血管肿瘤队列:心血管疾病易导致癌症死亡率升高。
背景:心血管疾病(CVD)和癌症是全球两大主要死因。鉴于这两种疾病的高发病率,了解心血管疾病患者癌症死亡率的疾病负担非常重要:我们的目的是评估与无心血管疾病的普通人群相比,心血管疾病患者是否有更高的恶性肿瘤相关死亡风险:我们进行了一项全国人群队列研究,选择了 2000 年 4 月 1 日至 2005 年 12 月 31 日期间荷兰的心血管疾病患者。根据年龄、性别和种族从荷兰人口中选择了一个参考队列。在对荷兰统计局的全国登记数据进行链接后,对截至2020年12月31日的死亡率随访数据进行了评估:结果:共选取了 2,240,879 人,平均随访 12 年(范围 0.4-21.0),其中 738,666 人为心血管疾病患者,平均年龄为 71 ± 15 岁。参照组的恶性肿瘤死亡率为84/1000人年,心血管疾病患者为118/1000人年,其中心力衰竭患者的恶性肿瘤死亡率最高,为258/1000人年。与参照组相比,心血管疾病患者的恶性肿瘤死亡风险更高:HR 1.35(95%CI 1.33-1.36)。静脉疾病(HR 2.27,95%CI 2.17-2.36)和外周动脉疾病(HR 1.87,95%CI 1.84-2.01)患者的风险最高:结果表明,心血管疾病易导致癌症死亡率升高。在所有心血管疾病亚型中,高血压患者的癌症死亡率最高,而静脉疾病和外周动脉疾病患者的危险性最高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.50
自引率
3.60%
发文量
192
审稿时长
1 months
期刊介绍: EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信